Eleven Biotherapeutics, Inc.

EBIO

Statistics

$0.82Share Price
$20 MMarket Cap
N/AEBIT / EV
N/AFCF / EV
N/AROIC
N/ACash ROIC
980.2%3yr Avg Revenue Growth
4.27Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

x mark Cannot calculate EBIT / Enterprise Value, company has negative EBIT.
x mark Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.
x mark Cannot calculate Return on Invested Capital, company has negative EBIT.
x mark Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.
check mark The 3 Year Average Revenue Growth Value of 980.2% ranks as Suspicious.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 4.27.

Company Description

Eleven Biotherapeutics, Inc. is a preclinical stage biopharmaceutical company, which engages in medical development. It involves in the management of proprietary protein engineering platform called AMP-Rx for the development and discovery of protein therapeutics to treat diseases of the eye. The company through its therapeutic approach, focuses on structural biology of cytokines to design and generate product candidate called EBI-031, that targets Diabetic Macular Edema diseases. Eleven Biotherapeutics was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 29.36%
purple wand Deep Value 24.71%
orange wand Quality Growth 44.22%
green wand Green Team 6.14%
red dot Red Rating 5.76%
yellow dot Yellow Rating 14.17%
green dot Green Rating 14.95%
New Spell Stocks
purple wand New Stocks Added!
orange wand New Stocks Added!